Completely inaccurate.
This from our OA patent filings
https://patentscope.wipo.int/search/en/detail.jsf?docId=US300735814&tab=PCTCLAIMS&_cid=P20-KUP95W-92398-2
Claim 17. The method according to claim 1, wherein treatment is by administering an injection by the intra-muscular (IM) or sub-cutaneous (SC) routes, intra-venously (IV), intra-articularly (IA), peri-articularly, topically, via suppositories or orally.
This from PAR announcement 24/3/20
Oh and just one of the reasons why injectible is preferred over oral. This from the TGA a couple of days ago in relation to Elmiron and its adverse effects (where the oral dosage is continuous and many time that of the injectible).
https://www.tga.gov.au/publication-issue/pentosan-polysulfate-sodium-and-pigmentary-maculopathy
Am I worried about oral PPS being a threat to PAR. No way.
Ann: POSITIVE TOP-LINE RESULTS FROM PRECLINICAL STUDY IN ARDS, page-68
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |